

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

Manuscript NO: 64555

Title: Differential diagnosis and management of immune checkpoint inhibitor-induced

colitis: A comprehensive review

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05230210

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: United States

Manuscript submission date: 2021-02-19

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-05 17:19

Reviewer performed review: 2021-07-09 04:23

Review time: 3 Days and 11 Hours

| Scientific quality | [] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish |
|--------------------|--|
| Language quality | [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection |
| Conclusion | [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection |
| Re-review | []Yes [Y]No |



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

| Peer-reviewer | Peer-Review: [Y] Anonymous [] Onymous |
|---------------|---------------------------------------|
| statements | Conflicts-of-Interest: [] Yes [Y] No |

SPECIFIC COMMENTS TO AUTHORS

I would like to thank the authors for presenting this important topic. I have some notes regarding the manuscript. Abstract: The keywords are very broad and do not reflect the topic. The core tip includes many unexplained abbreviations. Introduction: Please rewrite this sentence to be more clear: "It is graded from 1 to 5 with grade 1 being the mildest and grade 5 representing death." The authors mention: "Prompt diagnosis and management of ICIs induced colitis is crucial for optimal outcome">>>why diagnosis should be prompt considering that most of the differential diagnoses (except infection) will also require steroids i.e. same management? The subtitle "Interval" please clarify of what? e.g. Interval from drug infusion to colitis. The authors stated, " Overall mortality rate associated with ICIs induced colitis is 5% (225/3905). Sixty percent (135/225) of the fatality was from CTLA-4 inhibitor, 25.8% (58/225) from anti PD-1 or PD-L1 and 14.2% (32/225) from combined therapy">> is that a meta-analysis or an original study, kindly clarify in the text to know the significance of the numbers stated. Could the authors clarify whether in the 5% mortality, the incidence increases with severity of the colitis or is unrelated? There are a lot of subtitles without enumeration and sometimes get confusing, please enumerate. The authors didn't state the pathophysiology and risk factors of the ICI induced colitis in details; I think this is important before stating treatment options. Please add the following reference and state the differences in aim if possible (as there is a lot of similarities in the topic and presentation); Reference: Som, A., Mandaliya, R., Alsaadi, D., Farshidpour, M., Charabaty, A., Malhotra, N., & Mattar, M. C. (2019). Immune checkpoint inhibitor-induced colitis: A comprehensive review. World journal of clinical cases, 7(4), 405-418. https://doi.org/10.12998/wjcc.v7.i4.405